Safety and Efficacy of Moderate-dose Denosumab in Fibrous Dysplasia: Observational Results From a Phase 2 Clinical Trial
Moderate-dose denosumab may provide clinical benefits comparable to the high-dose regimen in adults with FD while potentially lowering associated risks. However, discrepancies in the duration of efficacy are an important potential safety concern.
Authors
- Babak Saboury (ORCID: https://orcid.org/0000-0002-8632-6292)
- Luis F de Castro (ORCID: https://orcid.org/0000-0003-3194-9780)
- Alison M Boyce (ORCID: https://orcid.org/0000-0003-2987-3887)
- Xiaobai Li (ORCID: https://orcid.org/0000-0001-9615-3543)
- Kelly Milligan
- Vivian Szymczuk (ORCID: https://orcid.org/0000-0002-3513-1671)
- Ramzy Ahmed
- Ibrahim I Elbashir
Institutions
- National Institutes of Health (US)
- Eastern Virginia Medical School (US)
- Society of Nuclear Medicine and Molecular Imaging (US)
- National Institute of Biomedical Imaging and Bioengineering (US)
- National Institute of Dental and Craniofacial Research (US)
- National Institutes of Health Clinical Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1210/clinem/dgae867
- Citations
- 3
- Primary Topic
- Bone Tumor Diagnosis and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.41